FDA Oversight Of Clinical Trial Investigators Questioned By Rep. Bliley
Executive Summary
FDA oversight of clinical trial investigators is questioned by the House Commerce Committee in a July 13 letter to the HHS Inspector General.
You may also be interested in...
Trial Recruiting, IRBs Could Be Upcoming Congressional Hearing Topics
A hearing to discuss FDA and NIH progress in complying with HHS Inspector General recommendations on institutional review boards is being planned for early May by House Government Reform/Criminal Justice, Drug Policy & Human Resources Subcommittee Chairman Mica (R-Fla.).
Trial Recruiting, IRBs Could Be Upcoming Congressional Hearing Topics
A hearing to discuss FDA and NIH progress in complying with HHS Inspector General recommendations on institutional review boards is being planned for early May by House Government Reform/Criminal Justice, Drug Policy & Human Resources Subcommittee Chairman Mica (R-Fla.).
FDA, NIH Gene Therapy Oversight Roles To Be Questioned By Rep. Waxman
Rep. Waxman (D-Calif.) plans to ask FDA how the agency balances the proprietary rights of sponsors with the expectation of greater public scrutiny of gene therapy trials.